Drugs / EPRATUZUMAB-CYS-TESIRINE
EPRATUZUMAB-CYS-TESIRINE
also known as
Adc adct-602 · ADCT-602 · Antibody-drug conjugate adct-602 · Epratuzumab tesirine · Epratuzumab-cys-sg3249 · Hll2-cys-pbd · HLL2-TESIRINE
targets CD22
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03698552 | Aug 2018 → Nov 2025 | B-cell acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPRATUZUMAB-CYS-TESIRINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297872 ↗ |
| Known as | Adc adct-602 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297872 ↗ |
| Known as | ADCT-602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03698552 ↗ |
| Known as | Antibody-drug conjugate adct-602 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297872 ↗ |
| Known as | Epratuzumab tesirine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297872 ↗ |
| Known as | Epratuzumab-cys-sg3249 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297872 ↗ |
| Known as | Hll2-cys-pbd | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297872 ↗ |
| Known as | HLL2-TESIRINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297872 ↗ |
| Route | Intravenous | “Patients receive ADCT-602 intravenously (IV) over 30 minutes on day 1.” NCT03698552 ↗ |
| Target | CD22 | “ADCT-602 is a novel CD22-targeting ADC” PMID 38324336 ↗ Apr 2024 |